by The Tutu Team | Oct 13, 2016 | Uncategorized
Pfizer was downgraded by an analyst who sees a lack of near-term catalysts. (iStockphoto) No. 2 drugmaker Pfizer (PFE) could become acquisitive post-breakup flop, but it will likely overpay for those M&A assets, said Jeffries analyst Jeffrey Holford as he... by The Tutu Team | Oct 11, 2016 | Uncategorized
Summary After its failed attempts for a merger with Allergan and AstraZeneca to bolster its drug portfolio, Pfizer has to heavily rely on its current blockbuster drugs. Pfizer’s blockbuster drugs face growth challenges such as losing patent protection,... 